Trial Profile

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retifanlimab (Primary) ; Tuparstobart (Primary) ; Verzistobart (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions
Acronyms PLATEAU

Most Recent Events

23 Aug 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
28 Jun 2024 Planned initiation date changed from 30 Jun 2024 to 30 Aug 2024.
23 Apr 2024 Planned End Date changed from 31 Dec 2027 to 31 Jan 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com